Search clinical trials for: combination panitumumab and vemurafenib

Total 5131 results

Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Center Eugene Marquis

Completed

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE)

Malignant Melanoma

France
University of Arkansas

Withdrawn

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Multiple Myeloma

United States
Takeda

Recruiting

An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer

Colorectal Cancer

Japan
University of Alabama at Birmingham

Recruiting

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Head and Neck Cancer

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Inova Health Care Services
Genentech, Inc.

Withdrawn

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Stage IIIB-C Melanoma

United States
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (PLANET)

Colorectal Cancer

Spain
Radboud University Medical Center

Terminated

Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus (PANORAMIC)

Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus

Netherlands
Takeda

Completed

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer (APOLLON)

Colorectal Cancer

Japan
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Terminated

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PURO)

Urinary Bladder Cancer

Germany
Cliniques universitaires Saint-Luc- Université...

Terminated

Preoperative Panitumumab and Radiotherapy in Rectal Cancer (PrePaRad)

Rectal Cancer

Belgium
Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (TRIP)

Metastatic Colo-rectal Cancer

Italy
Hellenic Cooperative Oncology Group

Completed

Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients

Colorectal Cancer

Greece
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Metastatic Colorectal Cancer

Spain
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Kidney Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer

United States
University of Utah

Terminated

Regorafenib + Panitumumab for Colorectal Cancers

KRAS and NRAS Wild-type Colorectal Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Matteo's Friends

Recruiting

Dynamic Changes in Circulating Tumour Cells Protein Expression (Liquid-DRER2)

Recurrence Free Survival

Italy
University of Alabama at Birmingham

Recruiting

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Gruppo Oncologico del Nord-Ovest
Bayer; Amgen

Recruiting

PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)

Colorectal Cancer

Italy
Jonsson Comprehensive Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Metastatic Colorectal Cancer
Amgen

Completed

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Solid Tumors | Oncology | Tumors
Associacio catalana per a la recerca oncologica...
Amgen

Unknown

A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy (ACTIVE)

Metastatic Colorectal Cancer

Spain
Athanassios Argiris
University of Pittsburgh; University of North Carolina, Chapel Hill

Withdrawn

Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies

Salivary Gland Malignancy

United States
Stanford University

Suspended

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pancreas Cancer

United States
University of Alabama at Birmingham

Withdrawn

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer (Panitumumab)

Metastatic Colon Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Colorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E Mutation

United States
Amgen

Completed

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Wild-type RAS Metastatic Colorectal Cancer
Amgen

Completed

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Colorectal Cancer | Non-Small Cell Lung Cancer | Prostate Cancer | Solid Tumors | Advanced Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Amgen

Active, not recruiting

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma

United States
Radboud University Medical Center
The Netherlands Cancer Institute; Isala

Recruiting

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COWBOY)

Melanoma, Malignant, of Soft Parts

Netherlands
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
Eben Rosenthal

Recruiting

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Carcinoma | Metastatic Malignant Neoplasm in the Lung

United States
Andrei Iagaru

Not yet recruiting

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head-and-neck Squamous Cell Carcinoma

United States
Federation Francophone de Cancerologie Digestive
Amgen

Active, not recruiting

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Metastatic Colorectal Cancer

France, Martinique
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Amgen

Completed

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

Colorectal Cancer

United States
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
Amgen

Withdrawn

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Oncology
Cliniques universitaires Saint-Luc- Université...
Cliniques Universitaires UCL de Mont-Godinne, Dr Joseph Kerger; Cliniques Saint-Pierre...

Unknown

Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) (PASCE)

Carcinoma, Squamous Cell

Belgium
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Non-small-cell Lung Cancer
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Celldex Therapeutics
Memorial Sloan Kettering Cancer Center

Completed

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Thyroid Cancer

United States
Georgetown University
Millennium Pharmaceuticals, Inc.

Terminated

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Spanish Cooperative Group for the Treatment of...

Completed

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (ULTRA)

Stage IV Colorectal Cancer

Spain

3

Subscribe